Liblau, Roland S. http://orcid.org/0000-0001-5477-5475
Latorre, Daniela http://orcid.org/0000-0003-1031-1534
Kornum, Birgitte R. http://orcid.org/0000-0002-2515-9451
Dauvilliers, Yves http://orcid.org/0000-0003-0683-6506
Mignot, Emmanuel J. http://orcid.org/0000-0002-6928-5310
Article History
Accepted: 1 June 2023
First Online: 3 July 2023
Competing interests
: R.S.L. has received grant support from GlaxoSmithKline and Roche and has consulted for Merck, Novartis, Biogen and Sanofi-Genzyme. B.R.K. has consulted for UCB Pharma, Lundbeck, Gubra and Orexia Therapeutics, has submitted patent applications within the field of narcolepsy and is a founder of the University of Copenhagen spin-out company Ceremedy ApS. Y.D. is a consultant for and has participated in advisory boards for Jazz Pharmaceuticals, UCB Pharma, Avadel, Idorsia, Orexia, Takeda and Bioprojet. In the last 3 years, E.J.M. received grant support from, is a consultant for or has participated in advisory boards for Apple, Avadel, Axsome, Huami, Harmony, Idorsia, Jazz Pharmaceuticals, Orexia/Centessa, Sunovion and Takeda. D.L. declares no competing interests.